GR3036091T3 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- GR3036091T3 GR3036091T3 GR20010400936T GR20010400936T GR3036091T3 GR 3036091 T3 GR3036091 T3 GR 3036091T3 GR 20010400936 T GR20010400936 T GR 20010400936T GR 20010400936 T GR20010400936 T GR 20010400936T GR 3036091 T3 GR3036091 T3 GR 3036091T3
- Authority
- GR
- Greece
- Prior art keywords
- pharmaceutically acceptable
- mixture
- pharmaceutical composition
- acceptable organic
- solid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 239000003463 adsorbent Substances 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000007903 gelatin capsule Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000008247 solid mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13040993A | 1993-10-01 | 1993-10-01 | |
| US26727394A | 1994-06-28 | 1994-06-28 | |
| US08/297,004 US5559158A (en) | 1993-10-01 | 1994-08-31 | Pharmaceutical composition |
| PCT/US1994/010096 WO1995009614A1 (en) | 1993-10-01 | 1994-09-09 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3036091T3 true GR3036091T3 (en) | 2001-09-28 |
Family
ID=27384007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20010400936T GR3036091T3 (en) | 1993-10-01 | 2001-06-19 | Pharmaceutical composition |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5559158A (el) |
| EP (1) | EP0721330B1 (el) |
| JP (1) | JPH09503501A (el) |
| KR (1) | KR100330442B1 (el) |
| AT (1) | ATE200023T1 (el) |
| AU (1) | AU685509B2 (el) |
| CA (1) | CA2167413A1 (el) |
| DE (1) | DE69426984T2 (el) |
| DK (1) | DK0721330T3 (el) |
| ES (1) | ES2156904T3 (el) |
| GR (1) | GR3036091T3 (el) |
| IL (1) | IL110915A (el) |
| PT (1) | PT721330E (el) |
| WO (1) | WO1995009614A1 (el) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69305093T2 (de) * | 1992-12-29 | 1997-04-17 | Abbott Lab | Inhibitoren der retroviralen protease |
| US5786500A (en) * | 1993-10-22 | 1998-07-28 | Abbott Laboratories | Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| AU8145198A (en) * | 1997-06-16 | 1999-01-04 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
| MY145265A (en) * | 1998-07-20 | 2012-01-13 | Abbott Lab | Amorphous ritonavir |
| US6894171B1 (en) | 1998-07-20 | 2005-05-17 | Abbott Laboratories | Polymorph of a pharmaceutical |
| WO2000074677A2 (en) * | 1999-06-04 | 2000-12-14 | Abbott Laboratories | Improved pharmaceutical formulations |
| US7141593B1 (en) | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
| IT1313624B1 (it) * | 1999-09-21 | 2002-09-09 | Archimica Spa Ora Clariant Lif | Procedimento per la sintesi del ritonavir |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| WO2001034119A2 (en) * | 1999-11-12 | 2001-05-17 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| KR100738276B1 (ko) * | 1999-12-09 | 2007-07-12 | 알자 코포레이션 | 항바이러스성 약제 |
| EP1248600B1 (en) | 2000-01-19 | 2008-05-14 | Abbott Laboratories | Improved hiv protease inhibitors pharmaceutical formulations |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| US6911214B2 (en) | 2000-09-05 | 2005-06-28 | Abbott Laboratories | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
| JP4547148B2 (ja) * | 2001-06-22 | 2010-09-22 | ベンド・リサーチ・インコーポレーテッド | 非晶質薬剤の吸着物の医薬組成物 |
| WO2003063833A1 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
| PL208114B1 (pl) * | 2002-02-26 | 2011-03-31 | Astrazeneca Ab | Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie |
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| MXPA06001417A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| PE20050374A1 (es) | 2003-09-05 | 2005-05-30 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc |
| US20050071270A1 (en) * | 2003-09-26 | 2005-03-31 | Ramirez Christopher W. | Process for remote recovery and creation of machine specific authentication keys for systems |
| CA2541634A1 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
| JP4890254B2 (ja) | 2003-10-27 | 2012-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ耐性突然変異体 |
| EP2311851A3 (en) | 2004-02-04 | 2011-05-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| PL1729730T3 (pl) | 2004-03-30 | 2009-06-30 | Euro Celtique Sa | Odporna na zniszczenie postać dawkowania zawierająca adsorbent i środek przeciwdziałający |
| US8075910B2 (en) | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
| CA2583472A1 (en) | 2004-10-01 | 2006-04-13 | Chao Lin | Hcv ns3-ns4a protease inhibition |
| MY141025A (en) | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
| WO2006090264A1 (en) * | 2005-02-28 | 2006-08-31 | Ranbaxy Laboratories Limited | A process for the synthesis of 2-amino-5-protected amino-3-hydroxy-1, 6-diphenylhexane or a salt thereof - an intermediate for antiviral drugs |
| US20100120855A1 (en) | 2005-07-29 | 2010-05-13 | Tibotec Pharmaceuticals Ltd. | Macrocylic inhibitors of hepatitis c virus |
| DK1919904T3 (da) | 2005-07-29 | 2014-04-07 | Janssen R & D Ireland | Makrocykliske inhibitorer af hepatitis-c-virus |
| ES2373685T3 (es) | 2005-07-29 | 2012-02-07 | Tibotec Pharmaceuticals | Inhibidores macrocíclicos del virus de la hepatitis c. |
| JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
| TWI412535B (zh) | 2005-07-29 | 2013-10-21 | Tibotec Pharm Ltd | Ｃ型肝炎病毒之大環抑制劑（五） |
| DK1919899T3 (da) | 2005-07-29 | 2011-08-01 | Tibotec Pharm Ltd | Makrocykliske inhibitorer af hepatitis C virus |
| PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| PL1919898T3 (pl) | 2005-07-29 | 2011-06-30 | Tibotec Pharm Ltd | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| CA2617679A1 (en) * | 2005-08-02 | 2007-02-08 | Steve Lyons | Inhibitors of serine proteases |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| AU2006315438A1 (en) | 2005-11-11 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| WO2007109080A2 (en) * | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
| MX2008012617A (es) * | 2006-03-31 | 2008-10-10 | Novartis Ag | Compuestos organicos. |
| US20100113443A1 (en) * | 2006-10-31 | 2010-05-06 | Wyeth | Liquid formulations of phospholipase enzyme inhibitors |
| US20100093725A1 (en) * | 2006-10-31 | 2010-04-15 | Wyeth | Semi-solid formulations of phospholipase enzyme inhibitors |
| JP2010508357A (ja) * | 2006-10-31 | 2010-03-18 | ワイス エルエルシー | ホスホリパーゼ酵素阻害剤の処方 |
| CA2669938C (en) * | 2006-11-15 | 2016-01-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
| CA2661338C (en) | 2006-11-17 | 2015-05-12 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| US8937080B2 (en) | 2007-02-08 | 2015-01-20 | Medivir Ab | Pyrimidine substituted macrocyclic HCV inhibitors |
| WO2008106058A2 (en) | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| GEP20125645B (en) | 2007-02-27 | 2012-09-25 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
| ES2381410T3 (es) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Terapia de combinación paa el tratamiento de infecciones por VHC |
| WO2009032198A1 (en) * | 2007-08-30 | 2009-03-12 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| CN103479584A (zh) * | 2008-05-02 | 2014-01-01 | 吉里德科学公司 | 固体载体颗粒在改善药物制剂加工性中的应用 |
| KR101016899B1 (ko) | 2008-06-03 | 2011-02-22 | 삼성에스디아이 주식회사 | 배터리 팩 및 그 충전 방법 |
| TW201012814A (en) | 2008-07-01 | 2010-04-01 | Centocor Ortho Biotech Products L P | Cyclopropyl polymerase inhibitors |
| WO2010070611A1 (en) | 2008-12-18 | 2010-06-24 | Ranbaxy Laboratories Limited | Atazanavir formulations |
| EP2396028A2 (en) | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
| US8945735B2 (en) | 2009-02-23 | 2015-02-03 | Samsung Sdi Co., Ltd. | Built-in charge circuit for secondary battery and secondary battery with the built-in charge circuit |
| MY169734A (en) | 2009-04-25 | 2019-05-14 | Hoffmann La Roche | Methods for improving pharmacokinetics |
| CN102844030A (zh) | 2010-01-29 | 2012-12-26 | 沃泰克斯药物股份有限公司 | 用于治疗丙型肝炎病毒感染的疗法 |
| JP6158702B2 (ja) * | 2010-04-09 | 2017-07-05 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | ｐＨの影響を改善したアタザナビル硫酸塩製剤 |
| WO2012109646A1 (en) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Treatment of hcv in hiv infection patients |
| WO2012164575A2 (en) | 2011-05-27 | 2012-12-06 | Hetero Research Foundation | Amorphous ritonavir co-precipitated |
| UA117375C2 (uk) | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
| EP3057976A1 (en) | 2013-10-17 | 2016-08-24 | Medivir Ab | Hcv polymerase inhibitors |
| EP3060554A1 (en) * | 2013-10-24 | 2016-08-31 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CN106749085B (zh) * | 2016-12-23 | 2019-05-24 | 东北制药集团股份有限公司 | 一种制备利托那韦的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903297A (en) * | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
| ATE296624T1 (de) * | 1990-11-19 | 2005-06-15 | Monsanto Co | Retrovirusprotease inhibitoren |
| IE20010533A1 (en) * | 1990-11-20 | 2003-03-05 | Abbott Lab | Intermediates for preparing retroviral protease inhibiting compounds |
| CA2056911C (en) * | 1990-12-11 | 1998-09-22 | Yuuichi Nagano | Hiv protease inhibitors |
| EP0532466A3 (en) * | 1991-09-12 | 1993-06-16 | Ciba-Geigy Ag | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use |
| HU221816B1 (hu) * | 1991-10-11 | 2003-01-28 | Bristol-Myers Squibb Pharma Company | Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények |
| CA2081970C (en) * | 1991-11-08 | 1997-07-08 | Joseph P. Vacca | Hiv protease inhibitors useful for the treatment of aids |
| US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| DE69305093T2 (de) * | 1992-12-29 | 1997-04-17 | Abbott Lab | Inhibitoren der retroviralen protease |
-
1994
- 1994-08-31 US US08/297,004 patent/US5559158A/en not_active Expired - Lifetime
- 1994-09-09 ES ES94928043T patent/ES2156904T3/es not_active Expired - Lifetime
- 1994-09-09 CA CA002167413A patent/CA2167413A1/en not_active Abandoned
- 1994-09-09 JP JP7510810A patent/JPH09503501A/ja not_active Ceased
- 1994-09-09 PT PT94928043T patent/PT721330E/pt unknown
- 1994-09-09 DK DK94928043T patent/DK0721330T3/da active
- 1994-09-09 EP EP94928043A patent/EP0721330B1/en not_active Expired - Lifetime
- 1994-09-09 WO PCT/US1994/010096 patent/WO1995009614A1/en not_active Ceased
- 1994-09-09 DE DE69426984T patent/DE69426984T2/de not_active Expired - Fee Related
- 1994-09-09 AT AT94928043T patent/ATE200023T1/de not_active IP Right Cessation
- 1994-09-09 AU AU77229/94A patent/AU685509B2/en not_active Ceased
- 1994-09-09 KR KR1019960700481A patent/KR100330442B1/ko not_active Expired - Fee Related
- 1994-09-11 IL IL11091594A patent/IL110915A/xx not_active IP Right Cessation
-
1996
- 1996-05-22 US US08/650,261 patent/US5610193A/en not_active Expired - Fee Related
-
2001
- 2001-06-19 GR GR20010400936T patent/GR3036091T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5559158A (en) | 1996-09-24 |
| KR100330442B1 (ko) | 2002-08-21 |
| PT721330E (pt) | 2001-09-28 |
| CA2167413A1 (en) | 1995-04-13 |
| ATE200023T1 (de) | 2001-04-15 |
| KR960703567A (ko) | 1996-08-31 |
| DK0721330T3 (da) | 2001-06-25 |
| AU685509B2 (en) | 1998-01-22 |
| IL110915A0 (en) | 1994-11-28 |
| EP0721330B1 (en) | 2001-03-28 |
| ES2156904T3 (es) | 2001-08-01 |
| US5610193A (en) | 1997-03-11 |
| WO1995009614A1 (en) | 1995-04-13 |
| EP0721330A1 (en) | 1996-07-17 |
| DE69426984D1 (de) | 2001-05-03 |
| JPH09503501A (ja) | 1997-04-08 |
| AU7722994A (en) | 1995-05-01 |
| DE69426984T2 (de) | 2001-11-22 |
| IL110915A (en) | 1999-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL110915A (en) | Solid pharmaceutical composition comprising an adsorbent or mixture of adsorbents adsorbed to a mixture of an organic solvent or mixture of solvents an hiv protease inhibiting compound and an acid or combination of acids | |
| CA2271196A1 (en) | Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability | |
| CA2135062A1 (en) | Pharmaceutical and Other Dosage Forms | |
| MY101847A (en) | Composition for solid pharmaceutical preparations of active vitamins d 3 and process for preparation thereof. | |
| CA2071623A1 (en) | Cyclodextrin composition | |
| AU5404490A (en) | Removal and destruction of volatile organic compounds from gas streams | |
| CA2214399A1 (en) | Soft gelatin capsule with a gelatin shell comprising xanthine derivative | |
| AU7780091A (en) | Percutaneous preparation containing estradiol | |
| CA2285979A1 (en) | Analgesic combination | |
| CA2039053A1 (en) | Material for adsorbing pyrogen | |
| EP1167354A3 (en) | Racemic huperzine A | |
| KR850001693A (ko) | 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 | |
| CA2126015A1 (en) | Resist materials | |
| IL108327A (en) | Pharmaceutical composition comprising 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent | |
| CA2179733A1 (en) | Anticonvulsant pseudofructopyranose sulfamates | |
| WO1999044595A3 (en) | Pharmaceutical compositions for ulcer | |
| AU579111B2 (en) | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | |
| AU2923389A (en) | A pharmaceutical composition | |
| AU3970793A (en) | Methods of manufacturing high dosage glutathione, the tablets and capsules produced thereby | |
| AU4807990A (en) | Antinephrotoxic perfusion solution | |
| BG102692A (en) | Pharmaceutical forms with delayed release, containing misolastin | |
| BG101884A (en) | Salts of the clavulanic acid | |
| AU3580995A (en) | Derivatives of carbohydrates and compositions containing them | |
| CA2166774A1 (en) | Pharmaceutical composition for immunomodulating and adjuvant treatment | |
| CA2341366A1 (en) | Micronised pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |